-
<![CDATA[FDA Approves Revumenib for Relapsed/Refractory NPM1-Mutant Acute Myeloid Leukemia]]>
24 Oct 2025 22:54 GMT
… for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 … -revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation
Syndax … in relapsed or refractory mNPM1 acute myeloid leukemia. News release. Syndax Pharmaceuticals …
-
FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation
24 Oct 2025 20:08 GMT
… inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 …
-
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
24 Oct 2025 17:58 GMT
… NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. … ) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Updated Results from the … in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia (Version 1.2026 – September …
-
Revolutionizing AML: CAR-T and CAR-NK Cell Therapies
25 Oct 2025 22:25 GMT
… disease.
Subject of Research: Acute Myeloid Leukemia (AML) and Immunotherapy
… therapy, CAR-NK therapy, acute myeloid leukemia, immunotherapy, tumor microenvironment, … release syndrome.
Tags: acute myeloid leukemia treatmentCAR T cell therapy advancementsCAR …
-
<![CDATA[The OncFive: Top Oncology Articles for the Week of 10/19]]>
25 Oct 2025 16:25 GMT
… old with relapsed or refractory acute myeloid leukemia (AML) harboring a susceptible NPM1 …
-
Unlocking Lactate’s Role in AML Prognosis
25 Oct 2025 13:59 GMT
… could redefine therapeutic paradigms for acute myeloid leukemia (AML), researchers have leveraged sophisticated … of leukemia.
Subject of Research: Acute Myeloid Leukemia, Lactate Metabolism, Histone Lactylation, Transcriptomics …
-
<![CDATA[FDA Approves Revuforj for R/R NPM1-Mutant AML]]>
25 Oct 2025 00:50 GMT
… treatment of relapsed or refractory acute myeloid leukemia (AML) with a susceptible … for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 … approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation?utm_ …
-
FDA OK’s revumenib for subset of relapsed, refractory AML
25 Oct 2025 00:44 GMT
… older with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin … with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin … or refractory NPM1 mutated acute myeloid leukemia and relapsed or refractory …
-
<![CDATA[FDA Approves Revumenib for NPM1-Mutated, Relapsed/Refractory AML]]>
24 Oct 2025 23:45 GMT
… with relapsed or refractory (RR) acute myeloid leukemia (AML) harboring a susceptible … for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 … approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation
2. …
-
<![CDATA[Revumenib Granted FDA Approval for R/R NPM1-Mutated AML]]>
24 Oct 2025 23:38 GMT
… with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin … for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 … relapsed or refractory NPM1 mutated acute myeloid leukemia. News release. Syndax Pharmaceuticals. …
About
© 1995-2025